Transatlantic Active Surveillance on Cardiovascular Safety of NuvaRing (TASC) (TASC)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00524771 |
Recruitment Status :
Completed
First Posted : September 5, 2007
Results First Posted : April 9, 2014
Last Update Posted : April 9, 2014
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Contraception |

Study Type : | Observational |
Actual Enrollment : | 34100 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Transatlantic Active Surveillance on Cardiovascular Safety of NuvaRing (TASC) |
Study Start Date : | September 2007 |
Actual Primary Completion Date : | March 2012 |
Actual Study Completion Date : | June 2012 |

Group/Cohort |
---|
1
Users of NuvaRing
|
2
Users of combined oral contraceptives
|
- Number of Participants With Venous Thromboembolism (VTE) [ Time Frame: Time to event analysis within 48 months ]Venous thromboembolism (VTE) associated with the use of hormonal contraceptives that contain both an estrogen and progestin.
- Number of Participants With Arterial Thromboembolism (ATE) [ Time Frame: Time to event analysis within 48 months ]Arterial Thromboembolism (ATE) associated with the use of hormonal contraceptives that contain both an estrogen and progestin.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- women who are prescribed NuvaRing® or a combined oral contraceptive and who are new users (Starters, restarters or switchers) of the formulation
Exclusion Criteria:
- women who do not consent to participate in the study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00524771
Germany | |
Berlin Center for Epidemiology and Health Research | |
Berlin, Germany, 10115 |
Principal Investigator: | Juergen C Dinger, MD, PhD | Center for Epidemiology and Health Research Berlin, Germany |
Responsible Party: | Juergen Dinger, MD, PhD, Principal Investigator, Center for Epidemiology and Health Research, Germany |
ClinicalTrials.gov Identifier: | NCT00524771 |
Other Study ID Numbers: |
ZEG2007_03 |
First Posted: | September 5, 2007 Key Record Dates |
Results First Posted: | April 9, 2014 |
Last Update Posted: | April 9, 2014 |
Last Verified: | March 2014 |
Contraception Contraceptive Vaginal Ring |